HC Wainwright reiterated their buy rating on shares of ObsEva SA (NASDAQ:OBSV) in a report issued on Wednesday. The brokerage currently has a $27.00 target price on the stock.

Other equities research analysts also recently issued reports about the company. Leerink Swann reaffirmed an outperform rating and issued a $18.00 price target on shares of ObsEva SA in a research report on Wednesday, August 16th. Zacks Investment Research raised ObsEva SA from a sell rating to a hold rating in a research report on Wednesday, July 19th. Finally, Royal Bank Of Canada began coverage on ObsEva SA in a research report on Thursday, September 14th. They issued an outperform rating and a $22.00 price target on the stock. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company presently has an average rating of Buy and an average target price of $23.00.

Shares of ObsEva SA (NASDAQ OBSV) traded up 0.81% on Wednesday, reaching $8.69. The company had a trading volume of 254 shares. The firm’s market capitalization is $257.49 million. The company has a 50-day moving average price of $7.73 and a 200-day moving average price of $7.73. ObsEva SA has a 52-week low of $6.77 and a 52-week high of $14.18.

ObsEva SA (NASDAQ:OBSV) last issued its quarterly earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.13). During the same quarter in the prior year, the business earned ($0.30) earnings per share. Equities research analysts forecast that ObsEva SA will post ($2.38) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.watchlistnews.com/obseva-sas-obsv-buy-rating-reiterated-at-hc-wainwright/1615952.html.

Large investors have recently modified their holdings of the company. Baker Avenue Asset Management LP acquired a new stake in shares of ObsEva SA in the first quarter valued at about $104,000. Paloma Partners Management Co acquired a new stake in shares of ObsEva SA in the first quarter valued at about $131,000. Iguana Healthcare Management LLC acquired a new stake in shares of ObsEva SA in the first quarter valued at about $260,000. Spark Investment Management LLC acquired a new stake in shares of ObsEva SA in the first quarter valued at about $518,000. Finally, Nexthera Capital LP acquired a new stake in shares of ObsEva SA in the first quarter valued at about $521,000. 48.46% of the stock is currently owned by institutional investors.

ObsEva SA Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Analyst Recommendations for ObsEva SA (NASDAQ:OBSV)

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with Analyst Ratings Network's FREE daily email newsletter.